Vaxcyte (NASDAQ:PCVX) & Tourmaline Bio (NASDAQ:TRML) Financial Review

Tourmaline Bio (NASDAQ:TRML) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, earnings, dividends and risk.

Profitability

This table compares Tourmaline Bio and Vaxcyte’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tourmaline Bio	N/A	-20.97%	-20.56%
Vaxcyte	N/A	-23.53%	-22.20%

Risk and Volatility

Tourmaline Bio has a beta of 2.32, meaning that its stock price is 132% more volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500.

Valuation and Earnings

This table compares Tourmaline Bio and Vaxcyte”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tourmaline Bio	N/A	N/A	-$42.12 million	($2.82)	-4.39
Vaxcyte	N/A	N/A	-$402.27 million	($4.60)	-17.93

Vaxcyte is trading at a lower price-to-earnings ratio than Tourmaline Bio, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

91.9% of Tourmaline Bio shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 11.0% of Tourmaline Bio shares are owned by company insiders. Comparatively, 3.1% of Vaxcyte shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and price targets for Tourmaline Bio and Vaxcyte, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tourmaline Bio	0	0	6	0	3.00
Vaxcyte	0	0	8	0	3.00

Tourmaline Bio currently has a consensus price target of $54.00, indicating a potential upside of 336.54%. Vaxcyte has a consensus price target of $127.71, indicating a potential upside of 54.86%. Given Tourmaline Bio’s higher probable upside, research analysts plainly believe Tourmaline Bio is more favorable than Vaxcyte.

Summary

Tourmaline Bio beats Vaxcyte on 8 of the 10 factors compared between the two stocks.

About Tourmaline Bio

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

About Vaxcyte

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.